FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386020261> ?p ?o ?g. }

• W4386020261 abstract "Background Inhaled corticosteroids (ICS) are the mainstay treatment for persistent asthma. Escalating treatment is required when asthma is not controlled with ICS therapy alone, which would include, but is not limited to, adding a long‐acting beta2‐agonist (LABA) or a long‐acting muscarinic antagonist (LAMA) or doubling the dose of ICS. Objectives To assess the efficacy and safety of adding a LABA or LAMA to ICS therapy versus doubling the dose of ICS in adolescents and adults whose asthma is not well controlled on medium‐dose (MD)‐ICS using a network meta‐analysis (NMA), and to provide a ranking of these treatments according to their efficacy and safety. Search methods We searched the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, Global Health, ClinicalTrials.gov, and the World Health Organization ICTRP for pre‐registered randomised controlled trials (RCTs) from January 2008 to 19 December 2022. Selection criteria We searched for studies including adolescents and adults with uncontrolled asthma who had been treated with or were eligible for MD‐ICS, comparing it to high‐dose (HD)‐ICS, ICS/LAMA, or ICS/LABA. We excluded cluster‐ and cross‐over RCTs. Studies were of at least 12 weeks duration. Data collection and analysis We conducted a systematic review and network meta‐analysis according to a previously published protocol. We used Cochrane’s Screen4ME workflow to assess search results. We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. The primary outcome is asthma exacerbations (moderate and severe). Main results We included 38,276 participants from 35 studies (median duration 24 weeks (range 12 to 78); mean age 44.1; 38% male; 69% white; mean forced expiratory volume in one second 2.1 litres and 68% of predicted). MD‐ and HD‐ICS/LABA likely reduce and MD‐ICS/LAMA possibly reduces moderate to severe asthma exacerbations compared to MD‐ICS (hazard ratio (HR) 0.70, 95% credible interval (CrI) 0.59 to 0.82; moderate certainty; HR 0.59, 95% CrI 0.46 to 0.76; moderate certainty; and HR 0.56, 95% CrI 0.38 to 0.82; low certainty, respectively), whereas HD‐ICS probably does not (HR 0.94, 95% CrI 0.70 to 1.24; moderate certainty). There is no clear evidence to suggest that any combination therapy or HD‐ICS reduces severe asthma exacerbations compared to MD‐ICS (low to moderate certainty). This study suggests no clinically meaningful differences in the symptom or quality of life score between dual combinations and monotherapy (low to high certainty). MD‐ and HD‐ICS/LABA increase or likely increase the odds of Asthma Control Questionnaire (ACQ) responders at 6 and 12 months compared to MD‐ICS (odds ratio (OR) 1.47, 95% CrI 1.23 to 1.76; high certainty; and OR 1.59, 95% CrI 1.31 to 1.94; high certainty at 6 months; and OR 1.61, 95% CrI 1.22 to 2.13; moderate certainty and OR 1.55, 95% CrI 1.20 to 2.00; high certainty at 12 months, respectively). MD‐ICS/LAMA probably increases the odds of ACQ responders at 6 months (OR 1.32, 95% CrI 1.11 to 1.57; moderate certainty). No data were available at 12 months. There is no clear evidence to suggest that HD‐ICS increases the odds of ACQ responders or improves the symptom or qualify of life score compared to MD‐ICS (very low to high certainty). There is no evidence to suggest that ICS/LABA or ICS/LAMA reduces asthma‐related or all‐cause serious adverse events (SAEs) compared to MD‐ICS (very low to high certainty). HD‐ICS results in or likely results in little or no difference in the included safety outcomes compared to MD‐ICS as well as HD‐ICS/LABA compared to MD‐ICS/LABA. The pairwise meta‐analysis shows that MD‐ICS/LAMA likely reduces all‐cause adverse events (AEs) and results in a slight reduction in treatment discontinuation due to AEs compared to MD‐ICS (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.77 to 0.96; 4 studies, 2238 participants; moderate certainty; and RR 0.51, 95% CI 0.26 to 0.99; 4 studies, 2239 participants; absolute risk reduction 10 fewer per 1000 participants; moderate certainty, respectively). The NMA evidence is in agreement with the pairwise evidence on treatment discontinuation due to AEs, but very uncertain on all‐cause AEs, due to imprecision and heterogeneity. Authors' conclusions The review findings suggest that MD‐ or HD‐ICS/LABA and MD‐ICS/LAMA reduce moderate to severe asthma exacerbations and increase the odds of ACQ responders compared to MD‐ICS whereas HD‐ICS probably does not. The evidence is generally stronger for MD‐ and HD‐ICS/LABA than for MD‐ICS/LAMA primarily due to a larger evidence base. There is no evidence to suggest that ICS/LABA, ICS/LAMA, or HD‐ICS/LABA reduces severe asthma exacerbations or SAEs compared to MD‐ICS. MD‐ICS/LAMA likely reduces all‐cause AEs and results in a slight reduction in treatment discontinuation due to AEs compared to MD‐ICS. The above findings may assist in deciding on a treatment option during the stepwise approach of asthma management. Longer‐term safety of higher than medium‐dose ICS needs to be addressed in phase 4 or observational studies given that the median duration of included studies was six months." @default.
• W4386020261 created "2023-08-22" @default.
• W4386020261 creator A5001137629 @default.
• W4386020261 creator A5021462482 @default.
• W4386020261 creator A5022076655 @default.
• W4386020261 creator A5028786727 @default.
• W4386020261 creator A5061532894 @default.
• W4386020261 date "2023-08-21" @default.
• W4386020261 modified "2023-10-10" @default.
• W4386020261 title "Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis" @default.
• W4386020261 cites W1492735157 @default.
• W4386020261 cites W1626773437 @default.
• W4386020261 cites W1857542727 @default.
• W4386020261 cites W1858555081 @default.
• W4386020261 cites W1883034450 @default.
• W4386020261 cites W1902576439 @default.
• W4386020261 cites W1950302841 @default.
• W4386020261 cites W1962391690 @default.
• W4386020261 cites W1963853409 @default.
• W4386020261 cites W1966091977 @default.
• W4386020261 cites W1969735103 @default.
• W4386020261 cites W1978582522 @default.
• W4386020261 cites W1982924223 @default.
• W4386020261 cites W1985171602 @default.
• W4386020261 cites W1989553661 @default.
• W4386020261 cites W1990444499 @default.
• W4386020261 cites W1991813083 @default.
• W4386020261 cites W1996099244 @default.
• W4386020261 cites W2003706075 @default.
• W4386020261 cites W2009191674 @default.
• W4386020261 cites W2012420530 @default.
• W4386020261 cites W2013599050 @default.
• W4386020261 cites W2014186397 @default.
• W4386020261 cites W2019643126 @default.
• W4386020261 cites W2022145213 @default.
• W4386020261 cites W2024265404 @default.
• W4386020261 cites W2031245994 @default.
• W4386020261 cites W2034106034 @default.
• W4386020261 cites W2038550888 @default.
• W4386020261 cites W2039439214 @default.
• W4386020261 cites W2041512941 @default.
• W4386020261 cites W2045066398 @default.
• W4386020261 cites W2046179969 @default.
• W4386020261 cites W2049638018 @default.
• W4386020261 cites W2053298480 @default.
• W4386020261 cites W2056722047 @default.
• W4386020261 cites W2057765075 @default.
• W4386020261 cites W2061683646 @default.
• W4386020261 cites W2063738853 @default.
• W4386020261 cites W2065069776 @default.
• W4386020261 cites W2065770911 @default.
• W4386020261 cites W2069177538 @default.
• W4386020261 cites W2070646431 @default.
• W4386020261 cites W2071270488 @default.
• W4386020261 cites W2072271497 @default.
• W4386020261 cites W2075535893 @default.
• W4386020261 cites W2077456532 @default.
• W4386020261 cites W2082273266 @default.
• W4386020261 cites W2086167722 @default.
• W4386020261 cites W2086332783 @default.
• W4386020261 cites W2088340248 @default.
• W4386020261 cites W2095088722 @default.
• W4386020261 cites W2097738211 @default.
• W4386020261 cites W2104675861 @default.
• W4386020261 cites W2105984267 @default.
• W4386020261 cites W2112894410 @default.
• W4386020261 cites W2116395845 @default.
• W4386020261 cites W2116458407 @default.
• W4386020261 cites W2118866729 @default.
• W4386020261 cites W2119147796 @default.
• W4386020261 cites W2126325768 @default.
• W4386020261 cites W2128450617 @default.
• W4386020261 cites W2136797108 @default.
• W4386020261 cites W2140441261 @default.
• W4386020261 cites W2141501933 @default.
• W4386020261 cites W2144555615 @default.
• W4386020261 cites W2144625636 @default.
• W4386020261 cites W2152149480 @default.
• W4386020261 cites W2155217850 @default.
• W4386020261 cites W2156098321 @default.
• W4386020261 cites W2157823046 @default.
• W4386020261 cites W2163008997 @default.
• W4386020261 cites W2163766572 @default.
• W4386020261 cites W2168316735 @default.
• W4386020261 cites W2169843278 @default.
• W4386020261 cites W2289833205 @default.
• W4386020261 cites W2293620483 @default.
• W4386020261 cites W2299177375 @default.
• W4386020261 cites W2317362217 @default.
• W4386020261 cites W2331642892 @default.
• W4386020261 cites W2414353440 @default.
• W4386020261 cites W2460666841 @default.
• W4386020261 cites W246286872 @default.
• W4386020261 cites W2464026584 @default.
• W4386020261 cites W2510809719 @default.
• W4386020261 cites W2517626453 @default.
• W4386020261 cites W2532791177 @default.
• W4386020261 cites W2546744840 @default.
• W4386020261 cites W2553940320 @default.
• W4386020261 cites W2588681363 @default.

• next